We're excited to share that Josie Ford was interviewed by Blood Cancers Today about her recently published study in Blood Advances, which investigates the efficacy of the drug combination duvelisib and romidepsin in patients with rare and aggressive blood cancers.
Patients with these types of blood cancers, relapsed or refractory peripheral and cutaneous T-cell lymphomas, may require stem cell transplants, but the disease needs to be brought under control before patients can undergo this treatment.
Their findings suggest that this drug combination offers a novel strategy to help these patients control the disease in real-world clinical settings to be eligible for stem cell transplants.
“This indicates that duvelisib-romidepsin can be a promising treatment for these relapsed or refractory patients who are aiming to bridge to allogeneic stem cell transplant,” said Ford.
